Results 321 to 330 of about 40,773 (330)

Abstract 565: Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression

Arteriosclerosis, Thrombosis, and Vascular Biology, 2018
Background: We previously reported a marked (~7-fold) increase in plasma PCSK9 concentrations in patients treated with monoclonal antibodies blocking PCSK9 action. It is unclear whether this pronounced increase in plasma PCSK9 is due to increased hepatic production of PCSK9, slow plasma clearance of the antibody/PCSK9 complex ...
Joshua Miles, Michael D. Shapiro, Sergio Fazio, Hagai Tavori, Carlota Oleaga   +4 more
openaire   +2 more sources

Oral PCSK9 Inhibitors

Current Atherosclerosis Reports
In this review, we will discuss the data from early clinical studies of MK-0616 and summarize clinical trials of other oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.The success of PCSK9 inhibition with monoclonal antibody injections has fueled the development of additional therapies targeting PCSK9, including oral formulations ...
Anandita, Agarwala, Ramsha, Asim, Christie M, Ballantyne   +2 more
openaire   +2 more sources

Effect of anti-PCSK9 drugs on the association of PCSK9 to LDL

European Atherosclerosis Journal
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that is known to interact with the LDL receptor, thereby promoting its degradation and blunting the uptake of LDL from the circulation. In this context, anti-PCSK9 monoclonal antibodies (mAbs) and siRNAs have been approved for the treatment of hypercholesterolaemia.
Sara Matteucci, Valentina Pravatà, Francesco Maria Esposito, Angela Pirillo, Liliana Grigore, Alberico Luigi Catapano   +5 more
openaire   +1 more source

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

Nature Genetics, 2003
M. Abifadel, M. Varret, J. Rabès, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, A. Derré, Ludovic Villéger, M. Farnier, I. Beucler, E. Bruckert, J. Chambaz, B. Chanu, J. Lecerf, G. Luc, P. Moulin, J. Weissenbach, Annick Prat, M. Krempf, C. Junien, N. Seidah, C. Boileau   +25 more
semanticscholar   +1 more source

PCSK9 in metabolism and diseases

Metabolism
PCSK9 is a serine protease that regulates plasma levels of low-density lipoprotein (LDL) and cholesterol by mediating the endolysosomal degradation of LDL receptor (LDLR) in the liver. When PCSK9 functions unchecked, it leads to increased degradation of LDLR, resulting in elevated circulatory levels of LDL and cholesterol.
Ajoolabady, Amir, Pratico, Domenico, Mazidi, Mohsen, Davies, Ian G., Lip, Gregory Y. H., Seidah, Nabil, Libby, Peter, Kroemer, Guido, Ren, Jun   +8 more
openaire   +1 more source

PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 Pathways

Inflammation, 2022
Longxiang Huang, Yuanjing Li, Zhe Cheng, Zi Lv, Suxin Luo, Yong Xia   +5 more
semanticscholar   +1 more source

A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.

Acta Pharmacologica Sinica
Weizhi Wang, Chao Liu, Jin-Que Luo, Lijuan Lei, Mingzhu Chen, Yuyan Zhang, Ren Sheng, Yining Li, Li Wang, Xinhai Jiang, Tong-Mei Xiao, Yuhao Zhang, Shun-Wang Li, Yexiang Wu, Yang Xu, Yan-ni Xu, Shuyi Si   +16 more
semanticscholar   +1 more source

Pushing the envelope with PCSK9

Nature Reviews Drug Discovery, 2021
openaire   +3 more sources

Binding of PCSK9 to circulating LDL: Effect of PCSK9 monoclonal antibodies on the LDL-bound PCSK9?

Atherosclerosis, 2018
D. De Stefano, A. Baragetti, A. Baragetti, N. Macrì, H. Tavori, S. Fazio, A.L. Catapano   +6 more
openaire   +2 more sources

PCSK9 Inhibitors and Cardiovascular Events

New England Journal of Medicine, 2015
Johann Auer, Carina Primus, Robert Berent   +2 more
openaire   +8 more sources